mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC, combining MMAE, a tubulin polymerization inhibitor, with a protease-sensitive Val-Cit peptide. It targets cancer cells by attaching to monoclonal antibodies, delivering the MMAE anticancer payload. The maleimide moiety can react with cysteine or other thiol molecule for bioconjugation. Reagent grade, for research purpose.
Usually ships within 24 hours.